Cytokinetics(CYTK)
Focus: Cytokinetics is a publicly-traded small-molecule biotech focused on cardiovascular, neurology, oncology, and rare diseases with one launched product (Myqorzo/aficamten) and a robust pipeline of 45+ active trials.
Profile data last refreshed 5h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
28+9 this month
Growing — net +9 jobs in 30d
11 jobs added vs 2 removed. Steady team buildout.
Should You Work at Cytokinetics?
AI assessmentCareer upside exists if you tolerate binary pipeline risk; strong for clinical/biotech specialists willing to ride a pre-profitability inflection story, risky for those seeking stable scaling.
Why Work Here
- First commercial product (Myqorzo) launched in 2024, offering early-stage exposure to commercialization in rare cardiology
- Deep pipeline across validated therapeutic areas: 13 Phase 3 programs including aficamten, omecamtiv mecarbil, reldesemtiv, and tirasemtiv provide multiple clinical catalysts
Data completeness
7/9 — Strong
Company HealthStrong
Pipeline
Late-stage
11 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$8M
Key Products
Launch16.2yr
First-in-class cardiac myosin inhibitor; recent approval represents company's debut commercial asset in a small, high-need rare disease market.
Help build intelligence for Cytokinetics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.